Drug Trial Radar · NCT03150056
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
73
Actual
Start
Jul 18, 2017
Primary completion
Jul 31, 2020
Study completion Jun 22, 2021
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic (m)CRPC. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of GSK525762 in combination with either abiraterone (Arm A) or enzalutamide (Arm B).
Conditions
- Solid Tumours
Interventions
GSK525762Drug
GSK525762 will be administered.
AbirateroneDrug
Abiraterone will be administered.
EnzalutamideDrug
Enzalutamide will be administered.
PrednisoneDrug
Prednisone will be administered as a concomitant medication in combination with abiraterone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 21.3 months
- Number of Participants With AEs Leading to Any Dose Reduction or DelaysTime frame: Up to 21.3 months
- Number of Participants Who Withdrew Due to Toxicity and Changes in Safety AssessmentTime frame: Up to 21.3 months
- Percentage of Participants With Greater Than or Equals to (>=)50 Percent (%) Decrease in Prostate-specific Antigen From Baseline (PSA50)Time frame: Up to 21.3 months
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Towson, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
New York, New York
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Madison, Wisconsin
GSK Investigational Site
Sydney, New South Wales, Australia
GSK Investigational Site
Clayton, Victoria, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Málaga, Spain
GSK Investigational Site
Sabadell (Barcelona), Spain
GSK Investigational Site
Santander, Spain
GSK Investigational Site
Glasgow, United Kingdom
GSK Investigational Site
Sutton, London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.